VAR-505
10 evidence topics · 1 source
Objective
Relative bioavailability and bioequivalence of capsule formulations
Location and study date
Registry status, dates, and site
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “VAR-505” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-05-21” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-05” |
| First posted | “2026-05-27” |
| Last update posted | “2026-10-29” |
| Site | “Celerion, Inc.”; “Tempe” |
Study design
Randomized, open-label, two-part crossover
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Intervention model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
| Part 1 sequences | “Part 1: Reference Formulation, then Test Formulation A”; “Part 1: Test Formulation A, then Reference Formulation” |
| Part 2 sequences | “Part 2: Reference Formulation, then Test Formulation B”; “Part 2: Test Formulation B, then Reference Formulation”; “Part 2: Reference Formulation, then Test Formulation C”; “Part 2: Test Formulation C, then Reference Formulation” |
Eligibility criteria
Healthy nonsmoking adults aged 18 to 55 years
Treatment
Oral reference and test formulations
| Intervention | Quoted record |
|---|---|
| Reference | “Varegacestat Reference Formulation” |
| Test formulations | “Varegacestat Test Formulation A”; “Varegacestat Test Formulation B”; “Varegacestat Test Formulation C” |
| Route | “Oral administration” |
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary endpoints: relative bioavailability by AUC and Cmax
Secondary endpoints: safety and tolerability
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (estimated) | “44” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- VAR-505 is known only from its registry record. The record lists the study as “Recruiting”, with an actual start on 2026-05-21 and estimated primary completion in 2027-05, and no results are available.
- The registry record names a reference formulation and test formulations A, B, and C without stating their strengths or composition, so the relationship between the test capsules and the capsules used in RINGSIDE or proposed for marketing cannot be determined from the record.
- The study enrolls healthy adults aged 18 to 55 years under fasting conditions, with an estimated enrollment of 44 participants.